Increased Oversight for FDA Opioid Drug Approvals
This act establishes new procedures for the Food and Drug Administration (FDA) regarding the approval of opioid drugs. If the FDA decides to approve an opioid drug against the recommendation of its advisory committee, the decision must be made personally by the FDA Commissioner and cannot be delegated. This aims to increase accountability and transparency in the process of bringing powerful pain medications to market, potentially impacting public safety and the availability of these substances.
Key points
Decisions to approve opioid drugs against advisory committee recommendations must be made personally by the FDA Commissioner.
If such an approval occurs, the Commissioner must submit a report to Congress with medical and scientific evidence and disclose potential conflicts of interest.
A drug approved in this manner cannot be marketed until the required report is submitted to Congress.
The Commissioner may be required to testify before Congress regarding their decision.
Expired
Citizen Poll